Compare Stocks: TARS, AGEN, and OSIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$7.87 +8.9%	$7.08	$2.71 ▼ $8.85	$326.07M	1.38	844,417 shs	2.08 million shs
OSIR Osiris Therapeutics	$18.99	$18.99	$7.01 ▼ $19.30	$655.69M	N/A	205,753 shs	N/A
TARS Tarsus Pharmaceuticals	$78.09 -1.2%	$69.42	$53.85 ▼ $91.53	$3.47B	0.54	747,573 shs	710,965 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+8.93%	+13.33%	-4.78%	+162.17%	+72.86%
OSIR Osiris Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	-1.19%	-1.54%	+6.33%	+23.64%	+51.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$7.87 +8.9%	$7.08	$2.71 ▼ $8.85	$326.07M	1.38	844,417 shs	2.08 million shs
OSIR Osiris Therapeutics	$18.99	$18.99	$7.01 ▼ $19.30	$655.69M	N/A	205,753 shs	N/A
TARS Tarsus Pharmaceuticals	$78.09 -1.2%	$69.42	$53.85 ▼ $91.53	$3.47B	0.54	747,573 shs	710,965 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+8.93%	+13.33%	-4.78%	+162.17%	+72.86%
OSIR Osiris Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	-1.19%	-1.54%	+6.33%	+23.64%	+51.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.40	Hold	$26.33	234.82% Upside
OSIR Osiris Therapeutics	0.00	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	2.80	Moderate Buy	$94.00	20.37% Upside

Current Analyst Ratings Breakdown

Latest TARS, AGEN, and OSIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	AGEN Agenus	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$40.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/8/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
9/4/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
8/21/2026	AGEN Agenus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00
8/11/2026	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00 ➝ $25.00
8/7/2026	AGEN Agenus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	TARS Tarsus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$100.00 ➝ $98.00
7/30/2026	AGEN Agenus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00 ➝ $14.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$114.20M	3.11	N/A	N/A	($8.17) per share	-0.96
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	$451.36M	7.59	N/A	N/A	$8.09 per share	9.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	$120K	$2.58	3.05	N/A	N/A	69.33%	-47.68%	57.73%	11/9/2026 (Estimated)
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	137.00	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest TARS, AGEN, and OSIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2026	Q2 2026	AGEN Agenus	$0.05	-$0.01	-$0.06	-$0.01	$34.00 million	$34.52 million
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.34	0.34
OSIR Osiris Therapeutics	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
OSIR Osiris Therapeutics	0.28%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	6.50%
OSIR Osiris Therapeutics	43.40%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	81	45.16 million	42.23 million	Optionable
OSIR Osiris Therapeutics	342	34.53 million	N/A	Not Optionable
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable

TARS, AGEN, and OSIR Headlines

Recent News About These Companies

Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares

4 hours ago | kalkinemedia.comK

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded by Barclays to Strong-Buy Rating

September 18 at 5:59 AM | marketbeat.com

William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

September 17 at 5:07 PM | marketbeat.com

Hsbc Holdings PLC Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS

September 12, 2026 | marketbeat.com

Wellington Management Group LLP Purchases 24,117 Shares of Tarsus Pharmaceuticals, Inc. $TARS

September 11, 2026 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in Stock

September 10, 2026 | insidertrades.com

Squarepoint Ops LLC Buys 54,791 Shares of Tarsus Pharmaceuticals, Inc. $TARS

September 10, 2026 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 10, 2026 | americanbankingnews.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts

September 10, 2026 | marketbeat.com

Bobak Azamian Sells 10,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

September 9, 2026 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $942,637.50 in Stock

September 9, 2026 | marketbeat.com

Jefferies Financial Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $105.00

September 8, 2026 | marketbeat.com

Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline

September 8, 2026 | visionmonday.comV

Legal & General Group Plc Makes New $1.75 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

September 7, 2026 | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by Jefferies Financial Group

September 5, 2026 | marketbeat.com

Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition

September 4, 2026 | marketscreener.comM

Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals

September 4, 2026 | finance.yahoo.com

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

September 4, 2026 | rttnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High - Should You Buy?

September 4, 2026 | marketbeat.com

Tarsus Pharmaceuticals Completes Acquisition of Alkeus, Adds Gildeuretinol for Stargardt Disease to Pipeline

September 4, 2026 | quiverquant.comQ

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

September 4, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TARS, AGEN, and OSIR Company Descriptions

Agenus NASDAQ:AGEN

$7.86 +0.65 (+8.93%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$7.85 -0.02 (-0.19%)

As of 09/18/2026 07:35 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Osiris Therapeutics OTCMKTS:OSIR

$18.99 0.00 (0.00%)

As of 04/17/2019

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Tarsus Pharmaceuticals NASDAQ:TARS

$78.09 -0.94 (-1.19%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$78.06 -0.03 (-0.03%)

As of 09/18/2026 07:30 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARS, AGEN, and OSIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARS, AGEN, and OSIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARS, AGEN, and OSIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TARS, AGEN, and OSIR Company Descriptions

Agenus NASDAQ:AGEN

Osiris Therapeutics OTCMKTS:OSIR

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARS, AGEN, and OSIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARS, AGEN, and OSIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARS, AGEN, and OSIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TARS, AGEN, and OSIR Company Descriptions

Agenus NASDAQ:AGEN

Osiris Therapeutics OTCMKTS:OSIR

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools